3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Rituximab
99
Cyclophosphamide
63
fludarabine phosphate
54
Peripheral Blood Stem Cell Transplantation
52
Mycophenolic Acid
33
Bortezomib
33
Whole-Body Irradiation
32
ibrutinib
29
Dexamethasone
27
Tacrolimus
25
Cyclosporine
25
Etoposide
22
Busulfan
22
Melphalan
20
Filgrastim
20
Methotrexate
18
Lenalidomide
18
Antilymphocyte Serum
18
Radiotherapy
16
zanubrutinib
14
Bendamustine Hydrochloride
14
Sirolimus
13
Calcium Dobesilate
11
Everolimus
10
venetoclax
9
ibritumomab tiuxetan
9
Prednisone
9
Cyclosporins
9
idelalisib
8
Indium
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Waldenstrom Macroglobulinemia
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled